Provexis, the AIM-quoted owner of the Fruitflow tomato-extract ingredient, appeared among the most volatile UK stocks on 23 September 2026. With shares priced around a penny and annual results due, small trades can move the stock sharply in percentage terms.
Provexis plc (LSE:PXS) was among the most volatile UK stocks on 23 September 2026. The Reading-based company develops and sells Fruitflow, a tomato extract that it describes as scientifically proven to inhibit platelet aggregation, for use in dietary supplements and functional foods.
The shares trade on AIM, the London Stock Exchange's growth market, at around a penny each. Investors following the stock are awaiting results for the year to 31 March 2026, progress on a Chinese health-claim application by partner BYHEALTH, and evidence of steadier Fruitflow sales after an uneven 2025. Its 52-week trading range has spanned roughly a penny.
Why Provexis (PXS) Is in Focus
Provexis ranks among the UK's more volatile shares. Part of the explanation is arithmetic: the 52-week range is 0.55p to 1.55p, so a move of a fraction of a penny represents a large percentage change. The Market Capitalisation is about £25.2 million, with roughly 2.35 billion shares in issue.
Company news flow has been limited in 2026. The most recent regulatory announcements found for this article were shareholding notifications from DSM Venturing in April and May, so the next results statement is likely to be the main scheduled catalyst.
What Does Provexis Do?
Provexis is a very small business; It has two employees. It commercialises Fruitflow through direct sales of the Fruitflow II SD ingredient and a consumer product, Fruitflow+ Omega-3.
Its long-standing partner is dsm-firmenich. Under arrangements effective January 2023, DSM's existing Fruitflow customers transferred to Provexis as direct customers, with royalties payable to DSM on a declining scale until 31 December 2026. In China, BYHEALTH, which Provexis describes as a £2 billion market capitalisation business, is pursuing regulatory approval for a new health claim for Fruitflow.
What Has Been Happening Recently?
On 30 September 2025 Provexis said its audit for the year to 31 March 2025 would miss the AIM Rule 19 deadline, as its new auditors completed their first engagement. Shares were suspended from 1 October and restored on 30 October 2025, when final results were published.
Half-year results to 30 September 2025, released on 31 December 2025, said a Fruitflow production run was completed in October 2025, two months late, and that several hundred thousand pounds of Fruitflow II SD had been ordered or sold after the period end. The company planned at least three production runs over the following 12 months.
On 16 April and 20 May 2026 Provexis reported that DSM Venturing's holding had fallen from 10.94% to 9.958% and then to 8.802%, the latter through a disposal of voting rights.
What Are the Numbers Saying?
For the year to 31 March 2025, Revenue rose 61% to £1.29 million, with Fruitflow II SD sales up 80% to £1.17 million. The operating loss narrowed to £452,000 from £604,000, and year-end cash was £708,000.
The first half of the current year was weaker. Revenue for the six months to 30 September 2025 fell 54% to £364,000, which the company linked to the delayed production run, and the operating loss widened to £309,000. Cash was £523,000 and net Assets £610,000. The auditor and directors have highlighted a material uncertainty related to going concern, reflecting funding needs for production runs and Royalty payments, and the company has said it intends to settle remaining 2026 royalties to DSM in shares.
Why Is the Share Price Attracting Attention?
The facts: Provexis has a low share price, a large number of shares in issue, lumpy revenue tied to production timing and a going-concern uncertainty. Its largest corporate shareholder, DSM Venturing, reduced its stake in the spring of 2026.
Possible interpretations: One possible interpretation is that the stock's swings reflect speculative positioning ahead of annual results and any news on the Chinese health claim. Some investors may view the post-period Fruitflow orders and planned production runs as grounds for recovery; others may focus on the reduced DSM stake, potential dilution from share-settled royalties and thin trading. Volatility shows how much a price has moved, not where it will go.
How Does the FTSE AIM All-Share Context Matter?
AIM hosts many early-stage and micro-cap companies whose shares can be Illiquid and prone to sharp moves. This article has not verified Provexis's inclusion in the FTSE AIM All-Share index, so the index is best read as a backdrop for comparing AIM stocks rather than a statement of membership.
There is no evidence that wider AIM moves caused Provexis's recent volatility. For a company of this size, the share price tends to respond to company-specific factors: production timing, customer orders, regulatory progress in China and funding.
What Could Investors Watch Next?
Several items could influence sentiment:
- Annual results: accounts for the year to 31 March 2026, due under AIM Rule 19 within six months of the year end; last year's were delayed.
- Fruitflow production and orders: whether planned production runs translated into higher full-year sales.
- China: any decision on BYHEALTH's Fruitflow health-claim application.
- DSM royalties and funding: the end of royalty obligations on 31 December 2026, any share issuance to settle them and the going-concern position.
The Bottom Line
Provexis appeared among the most volatile UK stocks on 23 September 2026. A share price near one penny, around 2.35 billion shares in issue and limited recent news help explain why modest trading can produce large percentage moves. The company's revenue grew strongly in the year to March 2025 but fell by more than half in the following six months because of a delayed production run, and its accounts carry a going-concern uncertainty. The annual results, production and order updates, the Chinese regulatory process and the end of DSM royalty obligations are the next markers. Higher volatility is not a signal of future returns.






Please wait processing your request...